Impact of different biochemical markers in serum of patients with benign and malignant liver diseases

Mokhtar N, Gouda I, Adel I. Cancer pathology registry 2003–2004 and time trend analysis. Department of Pathology, National Cancer Institute, Cairo University; 2007. Lok, 2001, AASLD practice guidelines: chronic hepatitis B, Hepatology, 34, 1225, 10.1053/jhep.2001.29401 Sangiovanni, 2004, Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance, Gastroenterology, 126, 1005, 10.1053/j.gastro.2003.12.049 El Nady, 2003, Gene expression in HCV-associated hepatocellular carcinoma – upregulation of a gene encoding a protein related to the ubiquitin-conjugating enzyme, Liver Int, 23, 329, 10.1034/j.1478-3231.2003.00862.x Bosch, 1999, Epidemiology of primary liver cancer, Semin Liver Dis, 19, 271, 10.1055/s-2007-1007117 Szabo, 2004, Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis, Pathol Oncol Res, 10, 5, 10.1007/BF02893401 Staib, 2003, TP53 and liver carcinogenesis, Hum Mutat, 21, 201, 10.1002/humu.10176 Davis, 2003, Projecting future complications of chronic hepatitis C in the United States, Liver Transpl, 9, 331, 10.1053/jlts.2003.50073 Habib, 2001, Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity, Hepatology, 33, 248, 10.1053/jhep.2001.20797 Kamal, 2000, Interferon therapy in patients with chronic hepatitis C and schistosomiasis, J Hepatol, 32, 172, 10.1016/S0168-8278(00)80207-X El Asser, 1994, Hepatitis-B markers in sera of Egyptian hepatoma patients, Qatar Univ Sci J, 14, 21 Zakhary, 1994, Biochemical and environmental studies on hepatoma patients in Egypt, Qatar Univ Sci J, 14, 39 Mohamed, 2005, Intrafamilial transmission of hepatitis C in Egypt, Hepatology, 42, 683, 10.1002/hep.20811 Daniele, 2004, Α-fetoprotein and ultrasonography screening for hepatocellular carcinoma, Gastroenterology, 127, S108, 10.1053/j.gastro.2004.09.023 Nguyen, 2002, Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis, Hepatology, 36, 410, 10.1053/jhep.2002.34744 Dawson-Saunders, 1994 Levrero, 2006, Viral hepatitis and liver cancer: the case of hepatitis C, Oncogene, 25, 3834, 10.1038/sj.onc.1209562 Kremsdorf, 2006, Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis, Oncogene, 25, 3823, 10.1038/sj.onc.1209559 Jeng, 2007, Tumor necrosis factor-α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma, Neoplasia, 9, 987, 10.1593/neo.07781 Byl, 1993, Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients, Gastroenterology, 104, 1492, 10.1016/0016-5085(93)90361-F Maki, 2007, Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma, Ann Surg Oncol, 14, 1182, 10.1245/s10434-006-9049-1 Kamal, 2006, Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis, Hepatology, 43, 771, 10.1002/hep.21117 Ataseven, 2006, The levels of ghrelin, leptin, TNF-α and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection, Mediators Inflamm, 4, 78380 Tilg, 1992, Serum levels of cytokines in chronic liver diseases, Gastroenterology, 103, 264, 10.1016/0016-5085(92)91122-K Oguey, 1992, Epidermal growth factor receptor in chronic bile duct obstructed rats: implications for maintenance of hepatocellular mass, Eur J Cell Biol, 59, 187 Burr, 1996, Transforming growth factor-alpha expression is altered during experimental hepatocarcinogenesis, J Pathol, 179, 276, 10.1002/(SICI)1096-9896(199607)179:3<276::AID-PATH573>3.0.CO;2-U Dash, 2007, Determinants of the variability of aflatoxin-albumin adduct levels in Ghanaians, J Toxicol Environ Health, 70, 58, 10.1080/15287390600748880 Mulder, 1999, Variability of glutathione S-transferase alpha in human liver and plasma, Clin Chem, 45, 355, 10.1093/clinchem/45.3.355 Di Bisceglie, 1998, Hepatocellular carcinoma, Hepatology, 28, 1161, 10.1002/hep.510280436 Dajani, 2001, Development of a rapid and sensitive immunofluorometric assay for glutathione S-transferase A, Clin Chem, 47, 867, 10.1093/clinchem/47.5.867 Fernandes, 1996, Elevations of hepatic quinone reductase, glutathione and α- and μ- class glutathione S-transferase isoforms in mice with chronic hepatitis: a compensatory response to injury, Arch Biochem Biophys, 331, 104, 10.1006/abbi.1996.0288 Bonkovsky, 1991, Iron and the liver, Am J Med Sci, 301, 32, 10.1097/00000441-199101000-00006 Kowdley, 1997, The role of iron in chronic viral hepatitis: implications for therapy, 312 El-Atrebi KA. Measurements of serum ferritin and iron stores in chronic liver disease due to hepatitis C virus. Faculty of Medicine, Cairo University; 1988. Farag FM, Ghunaim HR, Gamil T, Chareeb NA, Shamaa S, Nefea FA. Clinical significance of serum ferritin and alpha-fetoprotein in some liver diseases. In: International conference of the Egyptian society of tumor markers oncology, February 15–17, Cairo, Egypt; 1988. p. 189–204. El-Asqalani HM. Serum alpha-1 antitrypsin in malignant liver. Faculty of Medicine, Mansoura University; 1988. Kew, 1978, Α1-Antitrypsin deficiency and hepatocellular cancer, Br J Cancer, 37, 635, 10.1038/bjc.1978.93 Grizzi, 2007, Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma, J Transl Med, 5, 3, 10.1186/1479-5876-5-3 Silver, 1974, The detection of alpha 1-fetoprotein in patients with viral hepatitis, Cancer Res, 34, 244 Marrero, 2004, Newer markers for hepatocellular carcinoma, Gastroenterology, 127, S113, 10.1053/j.gastro.2004.09.024